Intraperitoneal Chemotherapy
The role of cytoreductive surgery and HIPEC for the treatment of primary and secondary peritoneal malignancies-experience from a tertiary care center in Germany
Langenbeck’s Archives of Surgery 2024 April 8 [Link] Mikko Reese, Ann-Kathrin Eichelmann, Tobias M Nowacki , Andreas Pascher, Judith C Sporn Abstract Purpose: Peritoneal surface malignancies (PSM) are commonly known to have a dismal prognosis. Over the past decades, novel techniques such as cytoreductive surgery (CRS), hyperthermic intraperitoneal chemotherapy (HIPEC), and pressurized intraperitoneal aerosol chemotherapy…
Read MoreIs extereme cytoreductive surgery beneficial to survival ın malignant peritoneal mesothelioma?
Acta Chirurgica Belgica 2024 February 14 [Link] Murat Can Mollaoğlu, Ufuk Karabacak, Meriç Emre Bostancı, Turan Eray Seven, Kürşat Karadayı Abstract Introduction: Malign peritoneal mesothelioma (MPM) is an uncommon disease that is difficult to treat. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) are the gold standards for treating MPM. Sometimes extreme cytoreductive surgery (eCRS) is…
Read More2022 PSOGI Consensus on HIPEC Regimens for Peritoneal Malignancies: Diffuse Malignant Peritoneal Mesothelioma
Annals of Surgical Oncology 2023 July 23 [Link] Vahan Kepenekian, Olivia Sgarbura, Frederic Marchal, Laurent Villeneuve, Shigeki Kusamura, Marcello Deraco Abstract Background: Diffuse malignant peritoneal mesothelioma (DMPM) is a rare and aggressive primary peritoneal disease, with recommended treatment, in eligible patients, of a combination of complete cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). As…
Read MoreAdjuvant dendritic cell-based immunotherapy after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with malignant peritoneal mesothelioma: a phase II clinical trial
Journal for Immunotherapy of Cancer 2023 August [Link] Michelle V Dietz, Katrien L A Quintelier, Job P van Kooten, Nadine L de Boer, Madelief Vink, Alexandra R M Brandt-Kerkhof, Cornelis Verhoef, Yvan Saeys, Joachim G J V Aerts, Marcella Willemsen, Sofie Van Gassen, Eva V E Madsen Abstract Background: Malignant peritoneal mesothelioma (MPM) is an…
Read MoreHigh-Risk Peritoneal Mesothelioma: Does Metronomic Chemotherapy Have a Role?
Indian Journal of Surgical Oncology 2023 June [Link] Praveen Kammar, Niharika Garach, Aditi Bhatt, Jay Anam, Vashisth Maniar, Adwaita Gore, Sanket Mehta Abstract Objective: To evaluate the feasibility, tolerance, and efficacy of OMCT (oral metronomic chemotherapy) after CRS + HIPEC for peritoneal mesothelioma in patients with poor prognostic factors: PCI > 20, incomplete CRS, poor…
Read MoreEstablishment of a Bayesian network model to predict the survival of malignant peritoneal mesothelioma patients after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy
International Journal of Hyperthermia 2023 [Link] Yan-Dong Su, Xin Zhao, Ru Ma, Yu-Bin Fu, Zhi-Ran Yang, He-Liang Wu, Yang Yu, Rui Yang, Xin-Li Liang, Xue-Mei Du, Yue Chen, Yan Li Abstract Objectives: To establish a Bayesian network (BN) model to predict the survival of patients with malignant peritoneal mesothelioma (MPM) treated with cytoreductive surgery (CRS)…
Read MorePressurized intraperitoneal aerosol chemotherapy, reasons for interrupting treatment: a systematic review of the literature
Pleura and Peritoneum 2023 April 19 [Link] Anne-Cecile Ezanno, Brice Malgras, Marc Pocard Abstract Objectives: Pressurized intraperitoneal aerosol chemotherapy (PIPAC) gives encouraging results in the treatment of peritoneal metastasis (PM). The current recommendations require at least 3 sessions of PIPAC. However, some patients do not complete the full treatment course and stop after only 1…
Read MoreCytoreductive surgery (CRS) and heated intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma: Canadian practices and outcomes
Journal of Surgical Oncology 2023 May 30 [Link] Melina Deban, Kadhim Taqi, Gregory C Knapp, Mikael Soucisse, Matt Curry, Lucas Sidéris, Pierre Dubé, Maher Al Khaldi, Nicole Jedrzejko, Geoff Porter, Carman Giacomantonio, Trevor Hamilton, Andrea MacNeill, Lloyd Mack, Antoine Bouchard-Fortier Abstract Introduction: Peritoneal mesothelioma (PM) is a rare malignancy originating from the peritoneal lining. Cytoreductive…
Read MorePrognostic role of CD74, CD10 and Ki-67 immunohistochemical expression in patients with diffuse malignant peritoneal mesothelioma: a retrospective study
BMC Cancer 2023 May 5 [Link] Yufei Liang, Chunying Li, Yingying Liu, Liang Tian, Dongliang Yang Abstract Background: Diagnosis and treatment of diffuse malignant peritoneal mesothelioma (DMPM) are still challenging. The aim of the present study was to explore the correlation between CD74, CD10, Ki-67 and clinicopathological parameters, and identify independent prognostic factors of DMPM.…
Read MorePrognostic significance of the immuno-peritoneal cancer index in peritoneal metastatic patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
Langenbeck’s Archives of Surgery 2023 May 6 [Link] Yasemin Yildirim, Selman Sokmen, Ali Durubey Cevlik, Tayfun Bisgin, Berke Manoglu, Funda Obuz Abstract Purpose: A valid comparison of immune function among different patients with different primary pathologies or even with different tumour burdens requires the common use of a reliable assessment of the patient’s condition. The…
Read More